Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
139.14
-4.84 (-3.36%)
Mar 24, 2026, 4:00 PM EDT - Market closed
Insmed Employees
Insmed had 1,664 employees as of December 31, 2025. The number of employees increased by 393 or 30.92% compared to the previous year.
Employees
1,664
Change (1Y)
393
Growth (1Y)
30.92%
Revenue / Employee
$364,437
Profits / Employee
-$767,293
Market Cap
29.99B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,664 | 393 | 30.92% |
| Dec 31, 2024 | 1,271 | 359 | 39.36% |
| Dec 31, 2023 | 912 | 176 | 23.91% |
| Dec 31, 2022 | 736 | 123 | 20.07% |
| Dec 31, 2021 | 613 | 92 | 17.66% |
| Dec 31, 2020 | 521 | 86 | 19.77% |
| Dec 31, 2019 | 435 | 62 | 16.62% |
| Dec 31, 2018 | 373 | 159 | 74.30% |
| Dec 31, 2017 | 214 | 53 | 32.92% |
| Dec 31, 2016 | 161 | 36 | 28.80% |
| Dec 31, 2015 | 125 | 36 | 40.45% |
| Dec 31, 2014 | 89 | 28 | 45.90% |
| Dec 31, 2013 | 61 | 20 | 48.78% |
| Dec 31, 2012 | 41 | -1 | -2.38% |
| Dec 31, 2011 | 42 | 2 | 5.00% |
| Dec 31, 2010 | 40 | 25 | 166.67% |
| Dec 31, 2009 | 15 | -82 | -84.54% |
| Dec 31, 2008 | 97 | 3 | 3.19% |
| Dec 31, 2007 | 94 | -63 | -40.13% |
| Dec 31, 2006 | 157 | 72 | 84.71% |
| Dec 31, 2005 | 85 | 30 | 54.55% |
| Dec 31, 2004 | 55 | 35 | 175.00% |
| Dec 31, 2003 | 20 | -3 | -13.04% |
| Dec 31, 2002 | 23 | -37 | -61.67% |
| Dec 31, 2001 | 60 | 20 | 50.00% |
| Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BeOne Medicines AG | 12,000 |
| BioNTech SE | 7,807 |
| Moderna | 4,700 |
| Genmab | 2,973 |
| Incyte | 2,844 |
| Alnylam Pharmaceuticals | 2,500 |
| argenx SE | 1,599 |
| Revolution Medicines | 883 |
INSM News
- 11 hours ago - Insmed: "Strong Buy" As Possible Label Expansion For ARIKAYCE Bodes Well - Seeking Alpha
- 1 day ago - Insmed Incorporated (INSM) Shareholder/Analyst Call Transcript - Seeking Alpha
- 1 day ago - Insmed Lung Infection Therapy Data Impresses, Analyst Sees Approval Path - Benzinga
- 1 day ago - Insmed Announces Positive Topline Results from Phase 3b ENCORE Study of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with MAC Lung Disease - PRNewsWire
- 14 days ago - Insmed Incorporated (INSM) Presents at Leerink Global Healthcare Conference 2026 Transcript - Seeking Alpha
- 19 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 21 days ago - Baron Health Care Fund Q4 2025 Contributors And Detractors - Seeking Alpha
- 22 days ago - Insmed Incorporated (INSM) Presents at TD Cowen 46th Annual Health Care Conference Transcript - Seeking Alpha